Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, raised $24 million by offering 4.8 million units at $5, the low end of the range of $5 to $7. The company offered 1.9 million more units than anticipated. Each...read more
Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, announced terms for its IPO on Friday. The Miami Beach, FL-based company plans to raise $17 million by offering 2.9 million shares and warrants at a price range...read more
The IPO market revved back to life with nine IPOs raising $5.4 billion, joined by crypto exchange Coinbase’s direct listing. SPAC activity continued to decline, with just two raising $700 million. Pipeline activity held steady, with 10 IPOs, six SPACs, and...read more
Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering. Pasithea is focused on the discovery and development of novel...read more
Preclinical biotech Pasithea Therapeutics prices upsized IPO at $5 low end
Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, raised $24 million by offering 4.8 million units at $5, the low end of the range of $5 to $7. The company offered 1.9 million more units than anticipated. Each...read more
Preclinical biotech Pasithea Therapeutics sets terms for $17 million IPO
Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, announced terms for its IPO on Friday. The Miami Beach, FL-based company plans to raise $17 million by offering 2.9 million shares and warrants at a price range...read more
US IPO Weekly Recap: Coinbase’s direct listing headlines a 9 IPO week
The IPO market revved back to life with nine IPOs raising $5.4 billion, joined by crypto exchange Coinbase’s direct listing. SPAC activity continued to decline, with just two raising $700 million. Pipeline activity held steady, with 10 IPOs, six SPACs, and...read more
Preclinical biotech Pasithea Therapeutics files for a $20 million IPO
Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering. Pasithea is focused on the discovery and development of novel...read more